Breast Re-irradiation After Second Ipsilateral Lumpectomy

Официальное название

Breast Re-irradiation After Second Ipsilateral Lumpectomy (BRASIL Trial)

Обзор

The purpose of this research study is to test the safety and possible harms of treating breast cancer with reirradiation, after breast surgery. The researchers want to find out what effects (good and bad) reirradiation has on people who have already received radiation before surgery.

Вмешательства

• Лучевая терапия Intensity modulated radiation therapy (IMRT)
  40 Gy total in 15 consecutive weekday sessions to the partial breast

Первичные конечные точки

• Rate of grade 3 or higher treatment-related adverse events (AEs) [Срок оценки: 1 year]

Вторичные конечные точки (5)

• Local recurrence-free survival (LRFS) [Срок оценки: 5 years]
• Overall survival (OS) [Срок оценки: 5 years]
• Distant metastasis-free survival (DMFS) [Срок оценки: 5 years]
• Mastectomy-free survival (MFS) [Срок оценки: 5 years]
• Change in patient-rated cosmesis [Срок оценки: Over 5 years]

Критерии участия

Критерии включения

• Diagnosed with ER+HER2- breast cancer
• Provision of signed and dated ICF
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Age ≥ 40 years
• Oncotype < 26 (postmenopausal) <16 (premenopausal), Low, or Ultra-Low index.
• Minimum interval of 18 months from last breast radiotherapy session.
• Prior radiation therapy in the form of brachytherapy, external beam MV photons, protons or intraoperative radiation are allowed with an upper total dose limit of 68 Gy (EQD2) for those patients with prior records available.
• Ipsilateral recurrence, unifocal < 3 cm with negative margins, N0, Tis and invasive (pathological staging)
• Eastern Cooperative Oncology Group (ECOG) ≤ 2
• Planning target volume: whole breast (PTV: WB) ratio < 1/2
• Life expectancy > 12 months
• Individuals able to become pregnant: agreement to use highly effective contraception starting at screening through treatment, and for 1 year after the end of PBI. Should a participant become pregnant or suspect that they are pregnant while participating in this study, they should notify the treating physician immediately.

A person able to become pregnant is any person assigned female at birth (regardless of gender identity, sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

• Has not undergone a hysterectomy or bilateral oophorectomy; or
• Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has not had menses at any time during the preceding 12 consecutive months)

Критерии исключения

• BRCA1/2 mutation or any other receptor subtypes
• Individuals assigned male at birth with breast cancer
• Pregnancy or breastfeeding
• Skin involvement
• Distant metastasis
• Patients with initial high-risk triple negative or HER-2 enriched breast cancer will be excluded from the trial. However, if the initial subtype is not known, patients will still be allowed to enroll, and the initial primary tumor information will be recorded as missing on the clinical forms.
• Other malignancies (except skin)
• Connective tissue disorder (e.g., scleroderma, lupus)
• Any other condition that may put a participant at higher risk, at the discretion of the investigator.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

США · 2 центра

• Lynn Cancer Institute at Baptist Health, Inc. — Boca Raton
• Miami Cancer Institute at Baptist Health, Inc. — Miami

Публикации

• Arthur DW, Winter KA, Kuerer HM, Haffty B, Cuttino L, Todor DA, Anne PR, Anderson P, Woodward WA, McCormick B, Cheston S, Sahijdak WM, Canaday D, Brown DR, Currey A, Fisher CM, Jagsi R, Moughan J, White JR. Effectiveness of Breast-Conserving Surgery and 3-Dimensional Conformal Partial Breast Reirradiation for Recurrence of Breast Cancer in the Ipsilateral Breast: The NRG Oncology/RTOG 1014 Phase 2 PMID 31750868
• Arthur DW, Winter KA, Kuerer HM, Haffty BG, Cuttino LW, Todor DA, Simone NL, Hayes SB, Woodward WA, McCormick B, Cohen RJ, Sahijdak WM, Canaday DJ, Brown DR, Currey AD, Fisher CM, Jagsi R, White J. NRG Oncology-Radiation Therapy Oncology Group Study 1014: 1-Year Toxicity Report From a Phase 2 Study of Repeat Breast-Preserving Surgery and 3-Dimensional Conformal Partial-Breast Reirradiation for In- PMID 28721885
• Olivotto IA, Whelan TJ, Parpia S, Kim DH, Berrang T, Truong PT, Kong I, Cochrane B, Nichol A, Roy I, Germain I, Akra M, Reed M, Fyles A, Trotter T, Perera F, Beckham W, Levine MN, Julian JA. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol. 2013 Nov 10;31(32 PMID 23835717

Идентификаторы

NCT: NCT06867484 · LCI-2023-ZEI-001

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗